NO20082934L - Antivirale nukleotider - Google Patents

Antivirale nukleotider

Info

Publication number
NO20082934L
NO20082934L NO20082934A NO20082934A NO20082934L NO 20082934 L NO20082934 L NO 20082934L NO 20082934 A NO20082934 A NO 20082934A NO 20082934 A NO20082934 A NO 20082934A NO 20082934 L NO20082934 L NO 20082934L
Authority
NO
Norway
Prior art keywords
formula
methods
antiviral nucleotides
antiviral
nucleotides
Prior art date
Application number
NO20082934A
Other languages
English (en)
Inventor
Keshab Sarma
Byoung-Kwon Chun
Jeremy Clark
Peiyuan Wang
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37608355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082934(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of NO20082934L publication Critical patent/NO20082934L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Forbindelser som har formelen I hvori R1 er som heri definert er Hepatitt C virus NS5b polymerase-inhibitorer. Videre omtalt er blandinger og metoder for inhibering av hepatitt-replikasjon og fremgangsmåter for fremstilling av forbindelser med formel I.
NO20082934A 2005-12-09 2008-06-30 Antivirale nukleotider NO20082934L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74931905P 2005-12-09 2005-12-09
PCT/EP2006/069060 WO2007065829A1 (en) 2005-12-09 2006-11-29 Antiviral nucleosides

Publications (1)

Publication Number Publication Date
NO20082934L true NO20082934L (no) 2008-09-02

Family

ID=37608355

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082934A NO20082934L (no) 2005-12-09 2008-06-30 Antivirale nukleotider

Country Status (25)

Country Link
US (1) US7754699B2 (no)
EP (1) EP1957510A1 (no)
JP (2) JP4979710B2 (no)
KR (1) KR101238461B1 (no)
CN (1) CN101336247B (no)
AR (1) AR056850A1 (no)
AU (1) AU2006324098C1 (no)
BR (1) BRPI0619563A2 (no)
CA (1) CA2632626C (no)
CR (1) CR10136A (no)
EC (1) ECSP088518A (no)
GT (1) GT200800095A (no)
HN (1) HN2006041184A (no)
IL (1) IL192002A0 (no)
MA (1) MA30057B1 (no)
MY (1) MY150667A (no)
NO (1) NO20082934L (no)
NZ (1) NZ568909A (no)
PE (1) PE20071131A1 (no)
RU (1) RU2422454C2 (no)
TW (1) TWI394759B (no)
UA (1) UA91255C2 (no)
UY (1) UY30004A1 (no)
WO (1) WO2007065829A1 (no)
ZA (1) ZA200804958B (no)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
WO2007095269A2 (en) * 2006-02-14 2007-08-23 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2745284A1 (en) * 2008-12-18 2010-06-24 F. Hoffmann-La Roche Ag Biomarkers for hcv treatment response
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
SG194404A1 (en) * 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
MX2011007194A (es) * 2009-01-07 2013-07-12 Scynexis Inc Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).
ES2513415T3 (es) * 2009-01-21 2014-10-27 F. Hoffmann-La Roche Ag Composiciones farmacéuticas que comprenden un profármaco inhibidor de la polimerasa del VHC
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI483950B (zh) 2009-09-21 2015-05-11 Gilead Sciences Inc 用於製備１’－取代碳核苷類似物之方法及中間物
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
BR122020020745B8 (pt) 2010-07-22 2023-10-31 Gilead Sciences Inc Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende
BR112013005872A2 (pt) 2010-09-22 2019-09-24 Alios Biopharma Inc compostos, composição farmacêutica e respectivos usos
TW201300106A (zh) 2010-11-09 2013-01-01 Hoffmann La Roche 治療ｈｃｖ感染之醫藥組合物
AU2011336632B2 (en) 2010-11-30 2015-09-03 Gilead Pharmasset Llc Compounds
EP2691409B1 (en) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
CN102775458B (zh) * 2011-05-09 2015-11-25 中国人民解放军军事医学科学院毒物药物研究所 β-D-(2’R)-2’-脱氧—2’-氟-2’-C-甲基胞苷衍生物的制备及用途
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
PL2709613T5 (pl) 2011-09-16 2020-12-14 Gilead Pharmasset Llc Metody leczenia hcv
US8507460B2 (en) 2011-10-14 2013-08-13 Idenix Pharmaceuticals, Inc. Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2794630A4 (en) 2011-12-22 2015-04-01 Alios Biopharma Inc SUBSTITUTED PHOSPHORTHIOAT NUCLEOTIDE ANALOGUE
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
CA2873315A1 (en) 2012-05-22 2013-11-28 Idenix Pharamaceuticals, Inc. D-amino acid compounds for liver disease
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
SG11201407336PA (en) 2012-05-25 2015-03-30 Janssen Sciences Ireland Uc Uracyl spirooxetane nucleosides
CN104379591A (zh) 2012-05-29 2015-02-25 弗·哈夫曼-拉罗切有限公司 用于制备2-脱氧-2-氟-2-甲基-d-呋喃核糖基核苷化合物的方法
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
KR102001280B1 (ko) 2012-10-08 2019-07-17 아이데닉스 파마슈티칼스 엘엘씨 Hcv 감염에 대한 2'-클로로 뉴클레오시드 유사체
WO2014066239A1 (en) 2012-10-22 2014-05-01 Idenix Pharmaceuticals, Inc. 2',4'-bridged nucleosides for hcv infection
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
AR094466A1 (es) 2013-01-14 2015-08-05 Hoffmann La Roche Proceso para la obtención de un derivado de fluorlactona
PT2950786T (pt) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Formulação de combinação de dois compostos antivirais
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014160484A1 (en) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
TWI678373B (zh) * 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
SI3349758T1 (sl) 2015-09-16 2022-08-31 Gilead Sciences, Inc. Postopki za zdravljenje okužb z virusom arenaviridae
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CN109414508A (zh) 2016-05-27 2019-03-01 吉利德科学公司 使用ns5a、ns5b或ns3抑制剂治疗乙型肝炎病毒感染的方法
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
JP7554841B2 (ja) 2020-03-12 2024-09-20 ギリアード サイエンシーズ， インコーポレイテッド １’－シアノヌクレオシドを調製する方法
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
AU2021296841B2 (en) 2020-06-24 2025-01-23 Gilead Sciences, Inc. 1'-cyano nucleoside analogs and uses thereof
SI4204421T1 (sl) 2020-08-27 2024-07-31 Gilead Sciences, Inc., Spojine in postopki za zdravljenje virusnih okužb
IL315102A (en) 2022-03-02 2024-10-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1521738A1 (ru) * 1987-12-18 1989-11-15 Институт биоорганической химии АН БССР Метил-2-О-бензоил-3-фтор-3-дезокси-Д-рибофуранозиды в качестве промежуточных продуктов в синтезе биологически активных 3 @ -фтор-3 @ -дезоксирибонуклеозидов
KR100719606B1 (ko) 1998-02-25 2007-05-17 에모리 유니버시티 2'-플루오로뉴클레오사이드
SK1512002A3 (en) 1999-07-30 2002-11-06 Abbott Gmbh & Co Kg 2-pyrazolin-5-ones
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (ko) 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
WO2002057425A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
AU2002330154A1 (en) 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
PL374781A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0312271A (pt) 2002-06-28 2007-11-06 Idenix Cayman Ltd compostos, composições e seus usos para o tratamento de infecções por flaviviridae
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and Flaviviridae mutation
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
EP2345657A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
EP1658302B1 (en) 2003-07-25 2010-08-25 IDENIX Pharmaceuticals, Inc. Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
CN1863813B (zh) * 2003-08-27 2011-03-30 生物区科学管理控股有限公司 作为治疗剂的三环核苷或核苷酸

Also Published As

Publication number Publication date
TWI394759B (zh) 2013-05-01
JP2009518354A (ja) 2009-05-07
MY150667A (en) 2014-02-28
AU2006324098B2 (en) 2011-02-24
GT200800095A (es) 2009-10-08
CR10136A (es) 2008-11-18
TW200745151A (en) 2007-12-16
CA2632626A1 (en) 2007-06-14
JP4979710B2 (ja) 2012-07-18
PE20071131A1 (es) 2007-11-30
CN101336247B (zh) 2013-01-23
KR20080079671A (ko) 2008-09-01
CA2632626E (en) 2007-06-14
EP1957510A1 (en) 2008-08-20
AR056850A1 (es) 2007-10-24
AU2006324098A1 (en) 2007-06-14
BRPI0619563A2 (pt) 2011-10-04
UA91255C2 (uk) 2010-07-12
ECSP088518A (es) 2008-09-29
JP2012097098A (ja) 2012-05-24
CN101336247A (zh) 2008-12-31
CA2632626C (en) 2011-10-11
MA30057B1 (fr) 2008-12-01
US7754699B2 (en) 2010-07-13
KR101238461B1 (ko) 2013-03-05
ZA200804958B (en) 2009-05-27
UY30004A1 (es) 2007-06-29
AU2006324098C1 (en) 2011-12-08
RU2008127750A (ru) 2010-01-20
US20070197463A1 (en) 2007-08-23
WO2007065829A1 (en) 2007-06-14
RU2422454C2 (ru) 2011-06-27
NZ568909A (en) 2011-10-28
HN2006041184A (es) 2010-09-10
IL192002A0 (en) 2008-12-29

Similar Documents

Publication Publication Date Title
NO20082934L (no) Antivirale nukleotider
NO341663B1 (no) Cyklopropyl-kondenserte indolobenzaepin HCV NS5B inhibitorer
NO20084645L (no) Cyklopropyl kondenserte indolobenzazepin HCV NS5B inhibitorer
NO20071274L (no) Inhibitorer av hepatitt C virus RNA-avhengig RNA polymerase, og sammensetninger og behandlinger ved anvendelse av samme.
NO20062185L (no) Hepatitt C virus-inhibitorer
NO20091591L (no) Hepatitt C virusinhibitorer
NO20071162L (no) Heterosykliske antivirale forbindelser
WO2007103550A3 (en) Substituted aminothiazole derivatives with anti-hcv activity
NO20070751L (no) Inhibitorer av HCV-replifikasjon
MX2012003170A (es) Compuestos heterociclicos antivirales.
ATE483712T1 (de) Hcv-ns5b-inhibitoren
ATE505475T1 (de) Nukleosidderivate als inhibitoren viraler polymerasen
MX2010002904A (es) N-fenil-dioxo-hidropirimidinas utiles como inhibidores de virus de hepatitis c (hcv).
NO20080879L (no) HCV-NS3-proteaseinhibitorer
EA201491179A1 (ru) 2',4'-дифтор-2'-метил замещенные нуклеозидные производные в качестве ингибиторов репликации рнк вируса гепатита с
TW200720285A (en) Nucleoside compounds for treating viral infections
EA200901101A1 (ru) Макроциклические соединения в качестве ингибиторов протеазы ns3 вгс
BR112012015951A2 (pt) 4 azido-nucleosídeos como compostos anti-hcv
DK2209789T3 (da) Cyclopropyl-kondenserede indolobenzazepin HCV NS5B-hæmmere
MY146923A (en) Novel piperazine compound, and use thereof as hcv polymerase inhibitor
ATE432922T1 (de) Substituierte 5-carboxyamidpyrazoles und ä1,2, 4ütriazole als viruzide
MX2011012541A (es) Compuestos heterociclicos antivirales.
MX2012006513A (es) Compuestos heterociclicos antivirales.
ATE498398T1 (de) Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus
MX2012002958A (es) Compuestos antivirales heterociclicos.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: F HOFFMANN-LA ROCHE AG, US

FC2A Withdrawal, rejection or dismissal of laid open patent application